了解2024年西澳大利亚的父母决定拒绝或推迟婴儿RSV免疫接种,nirsevimab
Shevaun Drislane1, Hannah Moore2, Katie Attwell1
1School of Social Sciences, Political Science and International Relations, University of Western Australia, Australia.
Vaccine
|December 19, 2025
概括
父母对安全性,疾病风险和替代策略的担忧影响了决定拒绝或推迟尼尔塞维玛布 (单克隆抗体) 对婴儿呼吸道同胞病毒 (RSV) 保护的决定.
科学领域:
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
- 儿科 儿科 儿科
背景情况:
- 呼吸道同胞性病毒 (RSV) 对婴儿构成重大健康风险.
- 单克隆抗体Nirsevimab于2024年在西澳大利亚引入,以保护符合条件的婴儿免受RSV感染.
- 了解家长的疫苗决策对于公共卫生倡议至关重要.
研究的目的:
- 探索家长拒绝或推迟为婴儿接种尼尔塞维马布免疫的原因.
- 调查家长对RSV感染的知识和看法.
- 了解更广泛的父母对婴儿免疫接种的态度.
主要方法:
- 用11名家长进行半结构面试进行的定性研究.
- 采访探讨了nirsevimab决定的理由,RSV知识和一般免疫态度.
- 采访回复的诱导和演编码和分析.
主要成果:
- 影响决策的关键因素包括安全问题和nirsevimab的潜在副作用.
- 缺乏了解或低估RSV疾病风险和负担是一个重要的因素.
- 其他风险减轻策略和医疗保健提供者的建议也影响了父母的选择.
结论:
- 父母对尼尔西维玛布的犹是由安全感知,风险评估和外部建议的复杂相互作用影响的.
- 这项研究提供了对澳大利亚尼尔塞维马布疫苗犹的新型定性见解.
- 这些发现可以为改善澳大利亚和全球RSV免疫计划推广和普及的战略提供信息.
更多相关视频
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
8.2K
13:00Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
4.0K
相关概念视频
01:51Vaccinations
51.1K
Overview
51.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.1K